

GENOME THERAPEUTICS CORP

Form 8-K

December 18, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): December 17, 2003

GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Massachusetts

(State or other jurisdiction of incorporation)

0-10824

(Commission File Number)

04-2297484

(I.R.S. Employer Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant's telephone number, including area code)

Page 1 of 4 pages.

ITEM 5. OTHER EVENTS

On December 17, 2003, Genome Therapeutics issued a press release announcing a common stock offering, which is attached hereto as Exhibit 99.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

99.1 Press Release issued by Genome Therapeutics Corp. on December 17, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By:

/s/ STEPHEN COHEN

Name: Stephen Cohen

Title: Senior Vice President and Chief
Financial Officer

Date: December 17, 2003

EXHIBIT INDEX

Exhibit Number

Description

99.1

Press Release issued by Genome Therapeutics Corp. on December 17, 2003.